ReviewDrug metabolism reviews2008
From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.
Review in Drug metabolism reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.Proceedings of the National Academy of Sciences of the United States of America · 2009Trial
- Drug-microbiota interactions: an emerging priority for precision medicine.Signal transduction and targeted therapy · 2023Review
- Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine.Nature biotechnology · 2023Article
- Maternal Plasma Metabolic Profile Demarcates a Role for Neuroinflammation in Non-Typical Development of Children.Metabolites · 2021Article
- Sources of Interindividual Variability.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Rare Coding Variants Associated with Breast Cancer.Advances in experimental medicine and biology · 2021Article
- A Review of the Important Role ofGenes · 2020Review
- Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial.The EPMA journal · 2020Article
- Quantitative systems pharmacology and the personalized drug-microbiota-diet axis.Current opinion in systems biology · 2017Review
- Proteomics and metabolomics in ageing research: from biomarkers to systems biology.Essays in biochemistry · 2017Review
- Personalized medicine: Genetic risk prediction of drug response.Pharmacology & therapeutics · 2017Review
- Head-and-neck squamous cell carcinoma risk in smokers: no association detected between phenotype and AHR, CYP1A1, CYP1A2, or CYP1B1 genotype.Human genomics · 2016Article
- Mirror, mirror on the wall: which microbiomes will help heal them all?BMC medicine · 2016Article
- [Porphyria cutanea tara].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016Review
- Current status of biomarker research in neurology.The EPMA journal · 2016Review
- Fangjiomics: revealing adaptive omics pharmacological mechanisms of the myriad combination therapies to achieve personalized medicine.Acta pharmacologica Sinica · 2015Article
- Predose and Postdose Blood Gene Expression Profiles Identify the Individuals Susceptible to Acetaminophen-Induced Liver Injury in Rats.PloS one · 2015Article
- A review of the role of electronic health record in genomic research.Journal of cardiovascular translational research · 2014Review
- Improved drug therapy: triangulating phenomics with genomics and metabolomics.Human genomics · 2014Review
- Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention.Cellular oncology (Dordrecht, Netherlands) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A brief history of human genetics and genomics is provided, comparing recent progress in those fields with that in pharmacogenetics and pharmacogenomics, which are subsets of genetics and genomics, respectively. Sequencing of the entire human genome, the mapping of common haplotypes of single-nucleotide polymorphisms (SNPs), and cost-effective genotyping technologies leading to genome-wide association (GWA) studies - have combined convincingly in the past several years to demonstrate the requirements needed to separate true associations from the plethora of false positives. While research in human genetics has moved from monogenic to oligogenic to complex diseases, its pharmacogenetics branch has followed, usually a few years behind. The continuous discoveries, even today, of new surprises about our genome cause us to question reviews declaring that "personalized medicine is almost here" or that "individualized drug therapy will soon be a reality." As summarized herein, numerous reasons exist to show that an "unequivocal genotype" or even an "unequivocal phenotype" is virtually impossible to achieve in current limited-size studies of human populations. This problem (of insufficiently stringent criteria) leads to a decrease in statistical power and, consequently, equivocal interpretation of most genotype-phenotype association studies. It remains unclear whether personalized medicine or individualized drug therapy will ever be achievable by means of DNA testing alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.